DE602007009574D1 - Gelzusammensetzung zur behandlung von mykose - Google Patents

Gelzusammensetzung zur behandlung von mykose

Info

Publication number
DE602007009574D1
DE602007009574D1 DE602007009574T DE602007009574T DE602007009574D1 DE 602007009574 D1 DE602007009574 D1 DE 602007009574D1 DE 602007009574 T DE602007009574 T DE 602007009574T DE 602007009574 T DE602007009574 T DE 602007009574T DE 602007009574 D1 DE602007009574 D1 DE 602007009574D1
Authority
DE
Germany
Prior art keywords
gel composition
treatment
mycosis
present
permeation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007009574T
Other languages
English (en)
Inventor
Tomohiro Okumura
Akiko Ochiai
Keizo Sakuda
Yoshiyuki Tatsumi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaken Pharmaceutical Co Ltd
Original Assignee
Kaken Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharmaceutical Co Ltd filed Critical Kaken Pharmaceutical Co Ltd
Publication of DE602007009574D1 publication Critical patent/DE602007009574D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
DE602007009574T 2006-12-28 2007-12-28 Gelzusammensetzung zur behandlung von mykose Active DE602007009574D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006354626 2006-12-28
PCT/JP2007/075303 WO2008081940A1 (ja) 2006-12-28 2007-12-28 真菌症治療用ゲル組成物

Publications (1)

Publication Number Publication Date
DE602007009574D1 true DE602007009574D1 (de) 2010-11-11

Family

ID=39588620

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007009574T Active DE602007009574D1 (de) 2006-12-28 2007-12-28 Gelzusammensetzung zur behandlung von mykose

Country Status (9)

Country Link
US (1) US8889155B2 (de)
EP (1) EP2116243B1 (de)
JP (1) JP5372523B2 (de)
AT (1) ATE482703T1 (de)
CA (1) CA2673976C (de)
DE (1) DE602007009574D1 (de)
ES (1) ES2350806T3 (de)
PT (1) PT2116243E (de)
WO (1) WO2008081940A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
HUE027470T2 (en) * 2010-09-17 2016-09-28 Abbell Ab Treatment of fungal infections
JP5754799B2 (ja) * 2010-12-21 2015-07-29 学校法人 聖マリアンナ医科大学 研磨カス飛散防止組成物
MY179756A (en) * 2013-10-03 2020-11-12 Dow Pharmaceutical Sciences Stabilized efinaconazole formulations
JP6611014B2 (ja) 2013-11-22 2019-11-27 ボシュ ヘルス アイルランド リミテッド 抗感染方法、抗感染組成物、および抗感染装置
CN107427585A (zh) * 2015-01-20 2017-12-01 百利高Api有限公司 艾菲康唑的晶型
KR102060546B1 (ko) * 2019-06-07 2019-12-30 주식회사 바이오빌리프 에피나코나졸을 함유하는 용액 형태의 국소 투여용 약학 조성물
WO2021054533A2 (ko) * 2019-09-17 2021-03-25 주식회사 바이오빌리프 산으로서 소르빈산을 포함하는 안정화된 에피나코나졸-함유 약학 조성물
KR20210032672A (ko) * 2019-09-17 2021-03-25 주식회사 바이오빌리프 에피나코나졸을 함유하는 안정화된 약학 조성물
WO2021054531A2 (ko) * 2019-09-17 2021-03-25 주식회사 바이오빌리프 항산화제를 포함하는 안정화된 에피나코나졸-함유 약학 조성물
KR20210032662A (ko) * 2019-09-17 2021-03-25 주식회사 바이오빌리프 킬레이트화제를 포함하는 안정화된 에피나코나졸-함유 약학 조성물
KR20210032665A (ko) * 2019-09-17 2021-03-25 주식회사 바이오빌리프 킬레이트화제 및 항산화제의 조합을 포함하는 안정화된 에피나코나졸-함유 약학 조성물
WO2021054535A2 (ko) * 2019-09-17 2021-03-25 주식회사 바이오빌리프 킬레이트화제, 항산화제, 및 산의 조합을 포함하는 안정화된 에피나코나졸-함유 약학 조성물
KR102266145B1 (ko) * 2019-09-26 2021-06-17 대봉엘에스 주식회사 비정질 에피나코나졸 고체 분산체

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6061518A (ja) * 1983-09-14 1985-04-09 Hisamitsu Pharmaceut Co Inc ゲル状外用組成物
JPH07100652B2 (ja) * 1987-05-22 1995-11-01 サンスタ−株式会社 透明状軟膏基剤
JPH02264723A (ja) * 1989-04-06 1990-10-29 Taisho Pharmaceut Co Ltd 抗真菌剤
JP3130350B2 (ja) * 1991-11-28 2001-01-31 積水化学工業株式会社 経皮吸収製剤
JP2768830B2 (ja) 1993-05-10 1998-06-25 科研製薬株式会社 アゾリルアミン誘導体
HU225416B1 (en) * 1993-05-10 2006-11-28 Kaken Pharma Co Ltd Azolylamine derivatives and pharmaceutical compositions of antifungal effect
US5601839A (en) 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5696105A (en) * 1996-03-14 1997-12-09 Hackler; Walter A. Antifungal nail composition
JPH1059847A (ja) * 1996-08-22 1998-03-03 Sansho Seiyaku Co Ltd 抗真菌剤
US5993787A (en) * 1996-09-13 1999-11-30 Johnson & Johnson Consumer Products, Inc. Composition base for topical therapeutic and cosmetic preparations
DE60042453D1 (de) 1999-07-28 2009-08-06 Kaken Pharma Co Ltd Verfahren zum nachweis pathogener mikroorganismen und antimikrobieller mittel, verfahren zum nachweis der arzneimittelwirkung antimikrobieller mittel und antimikrobielle mittel
AU2001268512A1 (en) * 2000-06-16 2002-01-02 Hercules Incorporated Chemically-modified peptides, compositions, and methods of production and use
US6676953B2 (en) * 2001-01-26 2004-01-13 Don L. Hexamer Antifungal composition and method for human nails
US6585963B1 (en) * 2001-02-15 2003-07-01 Watson Pharmaceuticals, Inc. Nail compositions and methods of administering same

Also Published As

Publication number Publication date
WO2008081940A1 (ja) 2008-07-10
US8889155B2 (en) 2014-11-18
CA2673976A1 (en) 2008-07-10
JPWO2008081940A1 (ja) 2010-04-30
EP2116243A4 (de) 2009-12-23
ATE482703T1 (de) 2010-10-15
CA2673976C (en) 2015-02-17
EP2116243B1 (de) 2010-09-29
PT2116243E (pt) 2010-10-26
US20100317695A1 (en) 2010-12-16
ES2350806T3 (es) 2011-01-27
JP5372523B2 (ja) 2013-12-18
EP2116243A1 (de) 2009-11-11

Similar Documents

Publication Publication Date Title
DE602007009574D1 (de) Gelzusammensetzung zur behandlung von mykose
CA2645110C (en) Pharmaceutical composition for external use
NZ596330A (en) Lxr modulators
ATE509617T1 (de) Phenytoinformulierungen und ihre verwendungen in der wundheilung
DOP2012000314A (es) Compuestos, composiciones de tiocetato y metodos de uso
MX2009004705A (es) Moleculas de enlace de albumina y usos de las mismas.
EA201000897A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
EP2985281A3 (de) Isoindolin-verbindungen zur behandlung von krebs
EA200601776A1 (ru) Метадоновые композиции местного действия и способы их применения
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
ATE497489T1 (de) Nichtsymmetrisches geliermittel
CY1109519T1 (el) Κεκορεσμενες και ακορεστες 3-πυριδυλο-βενζοκυκλοαλκυλομεθυλαμινες για τη θεραπεια πονων, καταθλιψεων και καταστασεων φοβου
EA200900211A1 (ru) Замещенные производные имидазолона, их получение и применение
EA200601288A1 (ru) Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
PH12020500091A1 (en) Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer
EP1743623A3 (de) Verwendung von Harnstoffverbindungen zur Förderung der Desquamation
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
DK1654253T3 (da) Substituerede 3-pyrrolidinindolderivater
EA201390703A1 (ru) Замещенный натрий-1н-пиразол-5-олат
UY29999A1 (es) "n-pirazinil-fenilsulfonamidas, procedimientos y compuestos intemedios utilizados en su preparacion, composiciones farmaceuticas que las contienen y aplicaciones"
ATE501719T1 (de) Methoden und zusammensetzungen zur beruhigung von mund- und nasenschleimhäuten
EA200301046A1 (ru) Комбинация действующих веществ с биорегуляторными свойствами
DE502004005924D1 (de) Antimykotisch wirksame nagellackformulierungen mit substituierten 2-aminothiazolen als wirkstoff
RU2008144304A (ru) Мазь "руфипрон"